Predictive value of the Luminex single antigen panel for detecting flow cytometry cross-match positivity
Moreno C, Burgos L, Perez C, Delgado JA, Mata JJ, Errasti P, Martín P, Merino J.
Department of Immunology, Clínica Universidad de Navarra, Faculty of Medicine, University of Navarra, 31008 Pamplona, Spain
Anti-human leukocyte antigen (HLA) antibodies are a major cause of allograft loss. Solid-phase immunoassays, notably Luminex technology, have lately begun to replace traditional techniques for detecting these antibodies. This platform, however, carries some restrictions in the type of antibodies it detects. For this reason, results using these new technologies must be correlated with results using traditional techniques that have proven clinical significance.
We have correlated flow cytometry cross-match (FCXM) outcomes with results from Luminex assays. Serum samples from patients awaiting transplantation who had known anti-HLA antibodies as detected by Luminex were incubated with lymphocytes expressing (a) 1 of the HLA antigens detected by the sera or (b) several of them. Of the 169 T-cell FCXMs we performed, in 92 cases the target cell expressed only 1 of the HLA antigens detected by the serum. The results obtained correlated well with Luminex data (r = 0.84).
A cutoff mean fluorescence intensity value of 6,500 for the Luminex single antigen assay yielded a sensitivity of 85% and specificity of 82% for detecting a positive FCXM. In the other 77 cases, the target cell expressed 2 or more of the HLA antigens detected by the serum. In this situation, the same cutoff proved a useful tool for differentiating negative from positive FCXMs.
CITA DEL ARTÍCULO Hum Immunol. 2012 May;73(5):517-21. doi: 10.1016/j.humimm.2012.02.022. Epub 2012 Mar 6